$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

HER-2 binding antagonists

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-038/17
  • A61K-039/395
출원번호 UP-0506079 (2000-02-16)
등록번호 US-7625859 (2009-12-16)
발명자 / 주소
  • Clinton, Gail M.
  • Evans, Adam
  • Henner, William D.
출원인 / 주소
  • Oregon Health & Science University
대리인 / 주소
    Davison, Barry L.
인용정보 피인용 횟수 : 0  인용 특허 : 58

초록

There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an iso lated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to th

대표청구항

We claim: 1. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 19-28, and fragments thereof of about 50 to 79 contiguous residues in length, wherein the polypeptide binds to the extracellular domain (ECD) of HER-2 with an affinity bindi

이 특허에 인용된 특허 (58)

  1. Plowman Gregory D. ; Culouscou Jean-Michel ; Shoyab Mohammed ; Siegall Clay B. ; Hellstrom Ingegerd ; Hellstrom Karl E., Antibodies to HER4, human receptor tyrosine kinase.
  2. Arakawa Tsutomu ; Kita Yoshiko, Antibody-induced apoptosis.
  3. Ring David B., Antigen-binding sites of antibody molecules specific for cancer antigens.
  4. Marks Jeffrey R. ; Vaughn James P. ; Inglehart James D., Antisense oligonucleotides against ERBB-2.
  5. McCabe Dennis E. (Middleton WI) Martinell Brian J. (Madison WI), Apparatus for genetic transformation.
  6. Cockerill George Stuart,GBX ; Carter Malcolm Clive,GBX ; Guntrip Stephen Barry,GBX ; Smith Kathryn Jane,GBX, Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
  7. Lupu Ruth ; Lippman Marc E., Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor.
  8. Sukhatme Vikas P. (Chicago IL), Cloning and expression of early growth regulatory protein genes.
  9. Greene Mark I. ; Qian Xiaolan, Compositions and methods of treating tumors.
  10. Mark I. Greene ; Donald M. O'Rourke ; Ramachandran Murali ; Byeong-Woo Park, Compositions and methods of treating tumors.
  11. Greene Mark I. ; Zhang Xin, Compounds that bind to p185 and methods of using the same.
  12. Mark David F. (Danville CA) Lin Leo S. (Fremont CA) Yu Lu Shi-da (Oakland CA) Wang Alice M. (Walnut Creek CA), Cysteine-depleted muteins of biologically active proteins.
  13. Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
  14. Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
  15. Carney, Walter P.; McKenzie, Sara J.; Weinberg, Robert A., Detection of neu p185 in cell lysates.
  16. Dubensky ; Jr. Thomas W. ; Polo John M. ; Jolly Douglas J. ; Driver David A., Eukaryotic layered vector initiation systems.
  17. Kenneth A. Thomas, Jr. ; Richard L. Kendall ; Corey K. Goldman ; William R. Huckle ; Andrew J. Bett, Gene therapy for inhibition of angiogenesis.
  18. Joni Kristin Doherty ; Gail M. Clinton, HER-2 binding antagonists.
  19. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel, HER2 extracellular domain.
  20. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel,DEX, HER2 extracellular domain.
  21. Michael R. Kozlowski ; Robert T. Lum ; Steven R. Schow ; Hugo O. Villar ; Micheal M. Wick, Heteroaryl-aryl ureas as IGF-1 receptor antagonists.
  22. Kim Sinil (Solana Beach CA), Heterovesicular liposomes.
  23. Kendall Richard L. ; Mao Xianzhi ; Thomas Kenneth A. ; Tebben Andrew, Human receptor tyrosine kinase, KDR.
  24. Kendall, Richard L.; Thomas, Kenneth A.; Mao, Xianzhi; Tebben, Andrew, Human receptor tyrosine kinase, KDR.
  25. Richard L. Kendall ; Xianzhi Mao ; Kenneth A. Thomas ; Andrew Tebben, Human receptor tyrosine kinase, KDR.
  26. Suni Jukka (Helsinki FIX) Vaheri Antti (Helsinki FIX), Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus.
  27. Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
  28. David Gary S. (La Jolla CA) Greene Howard E. (Carlsbad CA), Immunometric assays using monoclonal antibodies.
  29. Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., In vivo tumor detection assay.
  30. Adhip P. N. Majumdar, Isolation and characterization of a rat epidermal growth factor related protein.
  31. Greene Mark I. (Penn Valley PA) Dobashi Kunio (Gunma PA JPX) Davis James G. (Philadelphia PA) Hamuro Junji (Yokahama JPX), Ligand for the neu gene product.
  32. Lippman Marc E. (Bethesda MD) Lupu Ruth (Gaithersburg MD), Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses.
  33. Waterfield Michael D. (London GB2) Schlessinger J. (Rehovot CA ILX) Ullrich Axel (South San Francisco CA), Method of detecting truncated epidermal growth factor receptors.
  34. Baserga Renato ; Sell Christian ; Rubin Raphael, Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides.
  35. Renato Baserga ; Christian Sell ; Raphael Rubin, Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides.
  36. Bacus Sarah S. (Hinsdale IL), Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy.
  37. Raymond A. Koski, Methods and compositions for determining HER-2/neu expression.
  38. Singer,Elizabeth; Landgraf,Ralf; Slamon,Dennis J.; Eisenberg,David, Methods and materials for characterizing and modulating interaction between heregulin and HER3.
  39. Ho Wei-Hsien ; Osheroff Phyllis L., Methods involving sensory and motor neuron derived factor (SMDF).
  40. Greene Mark I., Methods of treating cancerous cells with anti-receptor antibodies.
  41. Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
  42. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  43. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  44. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  45. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  46. Clinton, Gail M., N-terminally truncated HER-2/neu protein as a cancer prognostic indicator.
  47. Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
  48. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., Protein related to but distinct from EGF receptor and antibodies reactive therewith.
  49. Boyd Andrew W.,AUX ; Simpson Richard,AUX ; Wicks Ian,AUX ; Ward Larry David,AUX ; Wilkinson David,AUX, Receptor-type tyrosine kinase and use thereof.
  50. Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
  51. Terman Bruce Israel ; Carrion Miguel Eduardo, Recombinant kinase insert domain containing receptor and gene encoding same.
  52. Miller A. Dusty (Seattle WA) Palmer Theo D. (Bellevue WA), Retroviral gene transfer into diploid fibroblasts for gene therapy.
  53. Bennett, Brian D.; Goeddel, David V.; Lee, James M.; Matthews, William; Tsai, Siao Ping; Wood, William I., SAL-S1 receptor protein tyrosine kinase agonist antibodies.
  54. Ho Wei-Hsien ; Osheroff Phyllis L., Sensory and motor neuron derived factor (SMDF).
  55. Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Single polypeptide chain binding molecules.
  56. Kluender Harold Clinton Eugene ; Benz Guenter Hans Heinz Herbert,DEX ; Brittelli David Ross ; Bullock William Harrison ; Combs Kerry Jeanne ; Dixon Brian Richard ; Schneider Stephan,DEX ; Wood Jill E, Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors.
  57. Margolis Ben Lewis ; Schlessinger Joseph, Treatment or diagnosis of diseases or conditions associated with a BLM domain.
  58. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., erbB-2 gene segments, probes, recombinant DNA and kits for detection.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트